7675-83-4 Usage
Chemical Properties
White or almost white granules or powder.
Originator
Arginine aspartate,Microbase Biotech
Co., Ltd.
Uses
L-Arginine L-Aspartate is used in investigation of the metabolic profiles of human breast cancer.
Manufacturing Process
1000 ml of polystyrene-trimethylbenzylammonium ion exchange resin were
converted into the chloride form by passing aqueous hydrochloride acid over
the resin. The resin was washed with distilled water to remove all traces of passed over the resin. A 10% excess of the calcium aspartate solution over
the theoretical ion-exchange capacity of the resin was used and the resin was
then washed with water until the wash water was free of chloride ions. At the
end of this treatment, the resin was in the aspartic acid form.
An aqueous solution containing 168.56 g of calcium aspartate and 49.44 g of
arginine dihydrochloride per litre was prepared, and this solution was passed
slowly over the aspartic acid form resin. The effluent liquid was collected in
fractions of 200 ml, then of 100 ml, and towards the end, in fractions of 50
ml. After about 1000 ml of eluate had been collected, the succeeding fractions
were examined very carefully for the presence of chloride ion. All the eluate
fractions prior to the first one containing traces of chloride, i.e. all the
chloride-free eluate fractions, were combined, the combined chloride eluates
amounted to about 1300 ml. The arginine present was determined by
Sakaguchis method and the total nitrogen in the combined eluates was also
determined. These determinations showed that the eluates contained from
270 to 300 g of arginine aspartare per litre. The combined eluates were
evaporated to a volume of about 500 ml and allowed to crystallize at a low
temperature (0°-4°C). After seeding with a crystal of arginine aspartate,
colourless crystals were obtained, they were filtered off, washed with aqueous
ethanol, and then dried. About 210 g, i.e. 70% of the theoretical yield, of
crystals having a decomposition point of 220°C was obtained. The mother
liquor from the first crystallization was evaporated down to a volume of about
150 ml. Ethanol was added to the solution until cloudiness which persisted
was obtained, the solution was cooled to 0°C and a second crop of crystals
was obtained. The size of this second crop was increased by adding further
ethanol after the major portion of the second crop had crystallized and
allowing the mixture to stand for 48 hours at 0°C. After separation, the
second fraction consisted of 75 g of a crystalline mass which had the same
physico-chemical and chemical properties as the main fraction.
Therapeutic Function
Tonic, Stimulant, Hepatoprotectant
Check Digit Verification of cas no
The CAS Registry Mumber 7675-83-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,6,7 and 5 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 7675-83:
(6*7)+(5*6)+(4*7)+(3*5)+(2*8)+(1*3)=134
134 % 10 = 4
So 7675-83-4 is a valid CAS Registry Number.
InChI:InChI=1/C6H14N4O2.C4H7NO4/c7-4(5(11)12)2-1-3-10-6(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
7675-83-4Relevant articles and documents
Effervescent systems using reaction doping agents
-
, (2008/06/13)
The effervescent tablet contains an effervescent system composed of carrier crystals of at least one solid, edible, organic acid, at least one component which forms gas by reacting with the acid with salt formation and at least one salt formed from the acid and the gas-forming component. A first layer of a different acid and a second layer of a (preferably acidic) salt of at least one of the two acids are applied to the carrier crystals. Of the total amount of the acid(s) used and of the gas-forming components, 10 to 40, in particular 10 to 20, percent by weight are in the form of the salts, preferably in the form of acidic salts. Carrier crystals are, in particular, citric acid, malic acid, tartartic acid, monosodium citrate and/or ascorbic acid. The first layer may contain gluconic acid delta-lactone and is preferably covered with citric acid, malic acid and/or tartaric acid. This is covered with a layer of a monosalt formed by reaction of part of the total amount of the gas-forming component with at least one of the acids used.
